Table 1.
Baseline demographics and clinical characteristics of pooled study cohorta
| Variable | Unmatched |
Matched |
||||
|---|---|---|---|---|---|---|
| Leuprolide | Degarelix | St. Diff | Leuprolide | Degarelix | St. Diff | |
| No. of patients | 12 448 | 1969 | 1887 | 1887 | ||
| Mean age (SD), y | 75.93 (7.48) | 76.10 (7.49) | −0.02 | 76.24 (6.74) | 76.18 (6.87) | 0.01 |
| Region, No. (%) | ||||||
| Northeast | 1807 (14.5) | 388 (19.7) | −0.14 | 374 (19.8) | 366 (19.4) | 0.01 |
| North central | 3695 (29.7) | 518 (26.3) | 0.08 | 484 (25.6) | 498 (26.4) | −0.02 |
| South | 4602 (37.0) | 733 (37.2) | 0.00 | 721 (38.2) | 703 (37.3) | 0.02 |
| West | 2333 (18.7) | 327 (16.6) | 0.06 | 308 (16.3) | 320 (17.0) | −0.02 |
| Raceb, No. (%) | ||||||
| Asian | 160 (1.3) | 19 (1.0) | 0.03 | 13 (0.7) | 19 (1.0) | −0.03 |
| Black | 974 (7.8) | 148 (7.5) | 0.01 | 159 (8.4) | 146 (7.7) | 0.03 |
| Hispanic | 363 (2.9) | 49 (2.5) | 0.02 | 46 (2.4) | 46 (2.4) | 0.00 |
| North American Native | 28 (0.5) | — | 0.01 | — | — | −0.02 |
| White | 7545 (60.6) | 1254 (63.7) | −0.06 | 1233 (65.3) | 1241 (65.8) | −0.01 |
| Unknown | 3378 (27.1) | 495 (25.1) | 0.04 | 433 (22.9) | 431 (22.8) | 0.00 |
| Cardiovascular event prognosticators, No. (%) | ||||||
| Acute or old MI | 4180 (33.6) | 683 (34.7) | −0.02 | 658 (34.9) | 654 (34.7) | 0.00 |
| Anxiety | 752 (6.0) | 119 (6.0) | 0.00 | 112 (5.9) | 112 (5.9) | 0.00 |
| Atrial fibrillation | 2168 (17.4) | 381 (19.3) | −0.05 | 333 (17.6) | 366 (19.4) | −0.05 |
| Coronary atherosclerosis | 9687 (77.8) | 1567 (79.6) | −0.04 | 1505 (79.8) | 1496 (79.3) | 0.01 |
| Revascularization (angioplasty/stent/coronary bypass graft) | 1238 (9.9) | 156 (7.9) | 0.07 | 133 (7.0) | 145 (7.7) | −0.03 |
| Diabetes | ||||||
| With complications | 6296 (50.6) | 1007 (51.1) | −0.01 | 988 (52.4) | 968 (51.3) | 0.02 |
| Without complications | 3895 (31.3) | 629 (31.9) | −0.01 | 587 (31.1) | 601 (31.8) | −0.02 |
| DVT | 515 (4.1) | 76 (3.9) | 0.01 | 76 (4.0) | 71 (3.8) | 0.01 |
| Edema | 1243 (10.0) | 236 (12.0) | −0.06 | 226 (12.0) | 223 (11.8) | 0.01 |
| Erectile dysfunction | 1425 (11.4) | 249 (12.6) | −0.04 | 239 (12.7) | 240 (12.7) | 0.00 |
| Foot ulcer | 404 (3.2) | 82 (4.2) | −0.05 | 69 (3.7) | 76 (4.0) | −0.02 |
| Hyperlipidemia | 10 236 (82.2) | 1671 (84.9) | −0.07 | 1596 (84.6) | 1600 (84.8) | −0.01 |
| Hypertension | 10 808 (86.8) | 1733 (88.0) | −0.04 | 1652 (87.5) | 1664 (88.2) | −0.02 |
| Intracranial or retroperitoneal hemorrhage | 166 (1.3) | 27 (1.4) | −0.01 | 23 (1.2) | 25 (1.3) | −0.01 |
| Ischemic heart disease | 10 276 (82.6) | 1643 (83.4) | −0.02 | 1581 (83.8) | 1567 (83.0) | 0.02 |
| Ischemic stroke | 2651 (21.3) | 430 (21.8) | −0.01 | 406 (21.5) | 406 (21.5) | 0.00 |
| Major trauma | 723 (5.8) | 107 (5.4) | 0.02 | 108 (5.7) | 100 (5.3) | 0.02 |
| Obesity | 1752 (14.1) | 279 (14.2) | 0.00 | 268 (14.2) | 263 (13.9) | 0.01 |
| Other disorders of thyroid gland | 443 (3.6) | 69 (3.5) | 0.01 | 62 (3.3) | 67 (3.6) | −0.02 |
| PE | 197 (1.6) | 26 (1.3) | 0.03 | 22 (1.2) | 24 (1.3) | −0.01 |
| Peripheral vascular disease | 3737 (30.0) | 599 (30.4) | −0.01 | 584 (30.9) | 568 (30.1) | 0.02 |
| Stable angina | 1535 (12.3) | 235 (11.9) | 0.01 | 207 (11.0) | 221 (11.7) | −0.02 |
| Systemic embolism | 218 (1.8) | 31 (1.6) | 0.02 | 24 (1.3) | 27 (1.4) | −0.01 |
| TIA | 419 (3.4) | 68 (3.5) | −0.01 | 62 (3.3) | 65 (3.4) | −0.01 |
| Prostate cancer prognosticators, No. (%) | ||||||
| Radiation therapies used in prostate cancer | 53 (0.4) | — | 0.00 | — | — | 0.00 |
| Prostatectomy | 395 (3.2) | 51 (2.6) | 0.04 | 52 (2.8) | 49 (2.6) | 0.01 |
| PSA test frequency, mean (SD) | 2.21 (2.20) | 2.10 (1.55) | 0.06 | 2.04 (1.40) | 2.10 (1.41) | 0.00 |
| Prostate cancer comorbidity index, mean (SD) | 35.44 (5.78) | 36.38 (6.16) | −0.16 | 36.33 (5.55) | 36.28 (5.35) | 0.00 |
a
Percentages may not add to 100% due to rounding. Values less than 11 have been suppressed with an em-dash to preserve patient privacy in accordance with our data use agreements. DVT = deep vein thrombosis; MI = myocardial infarction; PE = pulmonary embolism; PSA = prostate specific antigen; St. Diff = standardized difference; TIA = transient ischemic attack.
b
Race information was unavailable in the MarketScan database.